MET targeted therapy for lung cancer: clinical development and future directions

Yan Feng,1,2 Patrick C Ma1&ndash;31Translational Hematology and Oncology Research, 2Solid Tumor Oncology, 3Aerodigestive Oncology Translational Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USAAbstract: MET, the receptor for hepatocyte growth factor, has been identified...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Feng Y, Ma PC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1198cbd4fa954096b42e0400a73a3c59
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1198cbd4fa954096b42e0400a73a3c59
record_format	dspace
spelling	oai:doaj.org-article:1198cbd4fa954096b42e0400a73a3c592021-12-02T00:58:42ZMET targeted therapy for lung cancer: clinical development and future directions1179-2728https://doaj.org/article/1198cbd4fa954096b42e0400a73a3c592012-08-01T00:00:00Zhttp://www.dovepress.com/met-targeted-therapy-for-lung-cancer-clinical-development-and-future-d-a10669https://doaj.org/toc/1179-2728Yan Feng,1,2 Patrick C Ma1&ndash;31Translational Hematology and Oncology Research, 2Solid Tumor Oncology, 3Aerodigestive Oncology Translational Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USAAbstract: MET, the receptor for hepatocyte growth factor, has been identified as a novel promising target in various human malignancies, including lung cancer. Research studies have demonstrated that MET signaling plays important physiologic roles in embryogenesis and early development, whereas its deregulation from an otherwise quiescent signaling state in mature adult tissues can lead to upregulated cell proliferation, survival, scattering, motility and migration, angiogenesis, invasion, and metastasis in tumorigenesis and tumor progression. The MET pathway can be activated through ligand (hepatocyte growth factor, HGF) or MET receptor overexpression, genomic amplification, MET mutations, and alternative splicing. A number of novel therapeutic agents that target the MET/hepatocyte growth factor pathway have been tested in early-phase clinical studies with promising results. Phase III studies of MET targeting agents have recently been initiated. This paper will review the MET signaling pathway and biology in lung cancer, and the recent clinical development and advances of MET/hepatocyte growth factor targeting agents. Emphasis will be placed on discussing various unanswered issues and key strategies needed to optimize further clinical development of MET targeting personalized lung cancer therapy.Keywords: MET, HGF, lung cancer, targeted therapyFeng YMa PCDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 53-67 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Feng Y Ma PC MET targeted therapy for lung cancer: clinical development and future directions
description	Yan Feng,1,2 Patrick C Ma1&ndash;31Translational Hematology and Oncology Research, 2Solid Tumor Oncology, 3Aerodigestive Oncology Translational Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USAAbstract: MET, the receptor for hepatocyte growth factor, has been identified as a novel promising target in various human malignancies, including lung cancer. Research studies have demonstrated that MET signaling plays important physiologic roles in embryogenesis and early development, whereas its deregulation from an otherwise quiescent signaling state in mature adult tissues can lead to upregulated cell proliferation, survival, scattering, motility and migration, angiogenesis, invasion, and metastasis in tumorigenesis and tumor progression. The MET pathway can be activated through ligand (hepatocyte growth factor, HGF) or MET receptor overexpression, genomic amplification, MET mutations, and alternative splicing. A number of novel therapeutic agents that target the MET/hepatocyte growth factor pathway have been tested in early-phase clinical studies with promising results. Phase III studies of MET targeting agents have recently been initiated. This paper will review the MET signaling pathway and biology in lung cancer, and the recent clinical development and advances of MET/hepatocyte growth factor targeting agents. Emphasis will be placed on discussing various unanswered issues and key strategies needed to optimize further clinical development of MET targeting personalized lung cancer therapy.Keywords: MET, HGF, lung cancer, targeted therapy
format	article
author	Feng Y Ma PC
author_facet	Feng Y Ma PC
author_sort	Feng Y
title	MET targeted therapy for lung cancer: clinical development and future directions
title_short	MET targeted therapy for lung cancer: clinical development and future directions
title_full	MET targeted therapy for lung cancer: clinical development and future directions
title_fullStr	MET targeted therapy for lung cancer: clinical development and future directions
title_full_unstemmed	MET targeted therapy for lung cancer: clinical development and future directions
title_sort	met targeted therapy for lung cancer: clinical development and future directions
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/1198cbd4fa954096b42e0400a73a3c59
work_keys_str_mv	AT fengy mettargetedtherapyforlungcancerclinicaldevelopmentandfuturedirections AT mapc mettargetedtherapyforlungcancerclinicaldevelopmentandfuturedirections
_version_	1718403361389150208

MET targeted therapy for lung cancer: clinical development and future directions

Ejemplares similares